Assessment of Geriatric Evaluations Impact on New AML Guidance
ConditionAML, Adult
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age50+
SponsorAbramson Cancer Center at Penn Medicine
About this trial
The goal of the study is to measure physiologic age (there is no current formal definition but is meant to imply that patients should be evaluated holistically rather than on age alone) at baseline in newly diagnosed AML patients over 50 years receiving either intensive or non-intensive treatment. This information will be used to evaluate toxicity, early mortality, remission rates and long term survival.
Eligibility criteria
Qualifiers
AML diagnosis by peripheral flow cytometry and/or bone marrow aspirate and biopsy
New diagnosis being considered for new line of treatment
Age ≥ 50 years.
Performance status 0,1, and 2
Disqualifiers
Inability to understand or unable to sign a written informed consent
Unable to fill out questionnaires on their own and/or do not have someone to help complete them
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Abramson Cancer Center at Penn Medicine
Lead sponsor
Bristol-Myers Squibb
Collaborator
Source ClinicalTrials.gov